MX2021013442A - Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma. - Google Patents

Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma.

Info

Publication number
MX2021013442A
MX2021013442A MX2021013442A MX2021013442A MX2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A MX 2021013442 A MX2021013442 A MX 2021013442A
Authority
MX
Mexico
Prior art keywords
transnasal administration
powder preparation
producing same
preparation
transnasal
Prior art date
Application number
MX2021013442A
Other languages
English (en)
Spanish (es)
Inventor
Shunji Haruta
Yo Sonoda
Original Assignee
Shin Nippon Biomedical Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Nippon Biomedical Laboratories Ltd filed Critical Shin Nippon Biomedical Laboratories Ltd
Publication of MX2021013442A publication Critical patent/MX2021013442A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021013442A 2019-05-16 2020-05-01 Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma. MX2021013442A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019093150 2019-05-16
PCT/JP2020/018456 WO2020230676A1 (ja) 2019-05-16 2020-05-01 経鼻投与用の粉末製剤及びその製造方法

Publications (1)

Publication Number Publication Date
MX2021013442A true MX2021013442A (es) 2022-01-06

Family

ID=73290206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013442A MX2021013442A (es) 2019-05-16 2020-05-01 Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma.

Country Status (10)

Country Link
US (1) US12478581B2 (https=)
EP (1) EP3970696A4 (https=)
JP (2) JPWO2020230676A1 (https=)
KR (1) KR20220009407A (https=)
CN (1) CN113784703A (https=)
AU (1) AU2020273810B2 (https=)
BR (1) BR112021021841A2 (https=)
CA (1) CA3138846A1 (https=)
MX (1) MX2021013442A (https=)
WO (1) WO2020230676A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250270471A1 (en) * 2022-04-21 2025-08-28 Merck Sharp & Dohme Llc Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts
CN117503703B (zh) * 2023-11-09 2024-11-22 广州新济药业科技有限公司 一种左旋多巴鼻喷雾剂及其制备方法及应用
WO2025225629A1 (ja) * 2024-04-23 2025-10-30 株式会社メディラボRfp 経鼻投与用組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012818A1 (fr) * 1991-12-27 1993-07-08 Daiichi Pharmaceutical Co., Ltd. Preparation pharmaceutique pour application topique
JP3634380B2 (ja) * 1996-02-27 2005-03-30 帝人株式会社 粉末状経鼻投与組成物
JP3197221B2 (ja) * 1996-02-27 2001-08-13 帝人株式会社 吸収性が改善された粉末状経鼻投与組成物
JP3197222B2 (ja) 1996-02-28 2001-08-13 帝人株式会社 粉末状経鼻投与組成物
JP3197223B2 (ja) * 1996-02-28 2001-08-13 帝人株式会社 即効性と持続性を兼ね備えた粉末状経鼻投与用組成物
JP2001055323A (ja) * 1999-08-12 2001-02-27 Teijin Ltd 粉末状経鼻投与用組成物
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
KR20030027108A (ko) * 2001-07-05 2003-04-03 트렌스레셔널 리서치 가부시키가이샤 인슐린의 경비 투여용 조성물
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
JPWO2006064906A1 (ja) 2004-12-17 2008-06-12 小野薬品工業株式会社 非晶質性組成物
JP2006176461A (ja) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd 粒状物
ITRM20050443A1 (it) 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
CA2672134C (en) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Solid medicinal preparation containing mannitol or lactose
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CN101428009B (zh) * 2008-04-09 2013-01-09 上海医药工业研究院 胰岛素经鼻吸入粉雾剂
WO2009135646A2 (en) 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
ES2663335T3 (es) 2010-03-19 2018-04-12 Daiichi Sankyo Company, Limited Composición para administración transnasal y método para prepararla
JP2017036214A (ja) * 2013-12-10 2017-02-16 株式会社ダイセル 炭酸塩を含む口腔内崩壊錠剤用組成物及び口腔内崩壊錠剤
KR102634829B1 (ko) * 2016-06-24 2024-02-07 오피언트 파마슈티컬스, 인코퍼레이티드 알코올 사용 장애의 치료용 조성물, 장치 및 방법
EP3493789A2 (en) * 2016-08-05 2019-06-12 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
US11135217B2 (en) * 2016-12-26 2021-10-05 Shionogi & Co., Ltd. Manufacturing process of formulation having improved content uniformity
US11744967B2 (en) * 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Also Published As

Publication number Publication date
JP2024111203A (ja) 2024-08-16
EP3970696A4 (en) 2023-03-01
EP3970696A1 (en) 2022-03-23
US12478581B2 (en) 2025-11-25
BR112021021841A2 (pt) 2022-01-04
US20220183971A1 (en) 2022-06-16
JPWO2020230676A1 (https=) 2020-11-19
CN113784703A (zh) 2021-12-10
AU2020273810A1 (en) 2021-11-18
WO2020230676A1 (ja) 2020-11-19
AU2020273810B2 (en) 2025-10-09
KR20220009407A (ko) 2022-01-24
CA3138846A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
CR20170361A (es) Forma de dosificación que incluye una solución sólida de drogas amorfas
CL2018002914A1 (es) Formas de dosificación de liberación modificada disuasivas de abuso.
BR112017023674A2 (pt) suspensões farmacêuticas contendo partículas de fármaco, dispositivos para sua administração, e métodos de seu uso
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
CL2015003346A1 (es) Composiciones de cenicriviroc y métodos para realizarlas y utilizarlas
MX2021013442A (es) Formulacion en polvo para administracion intranasal y metodo de fabricacion de la misma.
ECSP17053843A (es) Formulación nasal en polvo para el tratamiento de hipoglicemia
AR087871A1 (es) Una composicion farmaceutica de rapida disolucion
IN2013MU03583A (https=)
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX349920B (es) Producción de principios farmacéuticos activos estériles.
MX2016015208A (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
AR101673A1 (es) Composición para el tratamiento de neuropatías y del dolor neuropático
MX386987B (es) Mini-tabletas de melatonina y métodos de fabricación de las mismas.
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
MX2019010229A (es) Composicion para la liberacion controlada de sustancias fisiologicamente activas y proceso para su preparacion.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
BR112017019364A2 (pt) dispersões sólidas